{
    "ticker": "APRH",
    "name": "Aprea Therapeutics, Inc.",
    "description": "Aprea Therapeutics, Inc. is a biotechnology company focused on the development of novel cancer therapeutics that target the p53 protein, a crucial tumor suppressor that is commonly mutated in various cancers. Founded in 2010 and headquartered in Durham, North Carolina, Aprea aims to leverage its proprietary drug development platform to create innovative treatments for patients with cancer. The company's lead product candidate, eprenetapopt (APR-246), is designed to restore the function of mutant p53, thus enabling the body to once again control cancer cell growth and survival. Aprea is committed to advancing its clinical programs, which include studies in hematologic malignancies and solid tumors, to address significant unmet medical needs in oncology. With a strong pipeline and a dedicated team, Aprea Therapeutics is poised to make significant contributions to cancer treatment and improve the lives of patients worldwide.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Durham, North Carolina, USA",
    "founded": "2010",
    "website": "https://www.apreatherapeutics.com",
    "ceo": "Shankar Musunuri",
    "social_media": {
        "twitter": "https://twitter.com/ApreaThera",
        "linkedin": "https://www.linkedin.com/company/aprea-therapeutics/"
    },
    "investor_relations": "https://investors.apreatherapeutics.com",
    "key_executives": [
        {
            "name": "Shankar Musunuri",
            "position": "CEO"
        },
        {
            "name": "Steven H. H. T. G. C. K. Y. Huang",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology",
            "products": [
                "Eprenetapopt (APR-246)"
            ]
        }
    ],
    "seo": {
        "meta_title": "Aprea Therapeutics, Inc. | Innovative Cancer Therapies",
        "meta_description": "Learn about Aprea Therapeutics, Inc., a pioneering biotechnology company developing novel cancer therapies targeting the p53 protein. Discover their mission and lead product, APR-246.",
        "keywords": [
            "Aprea Therapeutics",
            "Biotechnology",
            "Cancer Treatment",
            "p53",
            "Eprenetapopt",
            "APR-246"
        ]
    },
    "faq": [
        {
            "question": "What does Aprea Therapeutics focus on?",
            "answer": "Aprea Therapeutics focuses on developing cancer therapeutics that target the p53 protein."
        },
        {
            "question": "What is APR-246?",
            "answer": "APR-246 is Aprea's lead product candidate designed to restore the function of mutant p53 in cancer cells."
        },
        {
            "question": "Where is Aprea Therapeutics headquartered?",
            "answer": "Aprea Therapeutics is headquartered in Durham, North Carolina, USA."
        },
        {
            "question": "Who is the CEO of Aprea Therapeutics?",
            "answer": "Shankar Musunuri is the CEO of Aprea Therapeutics, Inc."
        },
        {
            "question": "When was Aprea Therapeutics founded?",
            "answer": "Aprea Therapeutics was founded in 2010."
        }
    ],
    "competitors": [
        "NVS",
        "ABBV",
        "AMGN",
        "ZTS"
    ],
    "related_stocks": [
        "BMY",
        "MRNA",
        "GILD",
        "CELG"
    ]
}